Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation & Amortization: 2021-2024

  • Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization fell 16.52% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.6 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2024, which is 16.52% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Accumulated Depreciation & Amortization of $1.4 million as of Q4 2024, which was down 16.52% from $1.6 million recorded in Q4 2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $1.6 million in Q4 2023 and a low of $53,000 during Q4 2021.
  • Its 3-year average for Accumulated Depreciation & Amortization is $1.2 million, with a median of $1.4 million in 2024.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization skyrocketed by 918.87% in 2022, and later dropped by 16.52% in 2024.
  • Quarterly analysis of 4 years shows Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization stood at $53,000 in 2021, then spiked by 918.87% to $540,000 in 2022, then soared by 201.48% to $1.6 million in 2023, then declined by 16.52% to $1.4 million in 2024.
  • Its last three reported values are $1.4 million in Q4 2024, $1.6 million for Q4 2023, and $540,000 during Q4 2022.